Skip to main content
. 2021 Jul 1;11:13667. doi: 10.1038/s41598-021-93213-9

Table 1.

Backgrounds and organ involvements of the subjects.

Total IL-12B rs6871626 LILRA3 rs103294
CC AC AA p value CC CT TT p value
Number 99 19 53 27 1 38 60
Age at onset (years) 31 ± 15 33 ± 16 30 ± 14 32 ± 15 0.91 45 35 ± 17 29 ± 13 0.052
Female 94 (95%) 18 (95%) 53 (100%) 23 (85%) 0.067 1 (100%) 36 (95%) 57 (95%) 0.99
Visual loss 3 (3%) 0 (0%) 2 (4%) 1 (4%) 0.51 0 (0%) 1 (3%) 2 (3%) 0.84
Hypertension 54 (56%) 10 (53%) 23 (45%) 21 (78%) 0.049* 1 (100%) 18 (50%) 35 (58%) 0.64
Ischemic heart disease 6 (6%) 1 (5%) 4 (8%) 1 (4%) 0.76 0 (0%) 1 (3%) 5 (8%) 0.23
Cerebrovascular event 9 (9%) 0 (0%) 5 (10%) 4 (15%) 0.088 0 (0%) 3 (8%) 6 (10%) 0.71
Renal replacement therapy 1 (1%) 0 (0%) 1 (2%) 0 (0%) 0.9 0 (0%) 0 (0%0 1 (2%) 0.33
Inflammatory bowel disease 7 (7%) 1 (5%) 2 (4%) 4 (15%) 0.16 0 (0%) 2 (6%) 5 (8%) 0.56
Ulcerative colitis 5 (5%) 1 (5%) 1 (2%) 3 (11%) 0.28 0 (0%) 2 (6%) 3 (5%) 0.97
Crohn disease 2 (2%) 0 (0%) 1 (2%) 1 (4%) 0.37 0 (0%) 0 (0%) 2 (3%) 0.16

Data are n (%) or mean ± standard deviation.